GSK liver drug wins FDA approval

GSK’s recent deal to license out a rare liver disease drug just got sweeter. The FDA on Thursday approved linerixibat to treat cholestatic itch in

Eli Lilly has positive phase 3 results for its triple agonist retatrutide in diabetes to go with its earlier encouraging data in obesity.

Subscribe for Updates

Copyright 2025 dijee Intelligence Ltd.   dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registration number 16808844